Basic information Safety Supplier Related

Bortezomib intermediates II

Basic information Safety Supplier Related

Bortezomib intermediates II Basic information

Product Name:
Bortezomib intermediates II
Synonyms:
  • Bortezomib Impurity 54 HCl
  • (S)-2-amino-N-((R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)-3-phenylpropanamide hydrochloride
  • Bortezomib intermediates II
  • (alphaS)-alpha-Amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]benzenepropanamide hydrochloride
  • BortezoMib InterMediate II
  • BortezoMib interMediates N-2
  • (αS)-α-Amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]-benzenepropanamide Monohydrochloride
  • Bortezomib intermediates I
CAS:
205393-21-1
MF:
C24H38BClN2O3
MW:
448.83412
Mol File:
205393-21-1.mol
More
Less

Bortezomib intermediates II Chemical Properties

Melting point:
197-198℃
storage temp. 
Inert atmosphere,Store in freezer, under -20°C
More
Less

Bortezomib intermediates II Usage And Synthesis

Uses

(αS)-α-Amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]-benzenepropanamide Monohydrochloride is a Bortezomib (B675700) intermediate which is used in the evaluation of bone-targeted proteasome inhibitors for myeloma.

Synthesis

7647-01-0

1187479-72-6

205393-21-1

GENERAL METHODS: (S)-N-Boc-2-amino-3-methoxypropionic acid (4.73 g, 21.58 mmol) was dissolved in anhydrous CH2Cl2 (120 mL) and cooled to -10 °C. HOBt (4.38 g, 32.37 mmol) and EDCI (6.2 g, 32.37 mmol) were added sequentially and stirred for 10 minutes. Intermediate 5 (8.19 g, 21.58 mmol) and DIPEA (9.77 g, 75.53 mmol) were then added. The reaction mixture was stirred at -10 °C for 1 hour, followed by continued stirring at room temperature for 15 hours. After completion of the reaction, the organic phase was washed sequentially with 10% hydrochloric acid, 5% NaHCO3 solution and brine and dried over anhydrous Na2SO4. Filtered and concentrated, the crude product obtained was directly used in the next step of the reaction. The borate ester prepared above was dissolved in ethyl acetate (30 mL) and ethyl acetate solution (55 mL) of 4.5 mol/L HCl was added slowly and dropwise at 0 °C. The reaction mixture was stirred at room temperature for 2 h. The ethyl acetate was removed by evaporation under reduced pressure. Methyl tert-butyl ether (MTBE) was added to the residue and filtered to give the glassy solid product 3a (7.8 g, 89.7% yield). The product was confirmed by 1H NMR (400 MHz, DMSO) and MS (ESI) characterization.

References

[1] Bioorganic and Medicinal Chemistry, 2018, vol. 26, # 14, p. 3975 - 3981
[2] Journal of Medicinal Chemistry, 2018,

Bortezomib intermediates IISupplier

Changzhou Kangte Pharmtech Co.,Ltd
Tel
0519-82813797 18994752886
Email
czkangte@hotmail.com
Bide Pharmatech Ltd.
Tel
400-164-7117 13681763483
Email
product02@bidepharm.com
Chengdu Aslee Biopharmaceuticals, Inc
Tel
028-85305008 02885305008
Email
2306208234@qq.com
Taizhou KEDE Chemical Co., Ltd
Tel
0576-84613060 13093829633
Email
sales@kedechemical.com
Chizhou Kailong Import and Export Trade Co., Ltd.
Tel
Email
xg01_gj@163.com